sar425899 sanofi dual agonist glp-1 glucagon Receptor occupancy of glucagon-like peptide 1/glucagon receptor in individuals with type 2 diabetes The effects of Fc fusion

FDA is requesting that the risk be removed from the warnings and precautions section of labeling for the GLP-1 obesity drugs Eli Lilly and Co.s Zepbound (tirzepatide) and Novo Nordisk A/S Saxenda (liraglutide) and Wegovy (semaglutide).

SafInside patented saffron extract, titrated at 2% safranal and 3% crocins

Are they worthy of all the hype? History is littered with failed weight-loss wonder drugs

Discover essential guidance on interactions, monitoring requirements, and safety considerations for combining GLP-1 receptor agonists with thyroid hormone replacement therapy.

Compounded GLP-1 alternatives for weight loss provide safe solutions